Waisman Biomanufacturing

Waisman Biomanufacturing Contract Manufacturing & Development (CDMO) Profile

Waisman Biomanufacturing, strategically part of the University of Wisconsin-Madison, has extensive experience in manufacturing a wide range of biologics for human clinical trials including plasmid DNA, cell therapeutics, viral vectors, vaccines, and recombinant proteins for internal and external biotech, non-profit, and academic partners.

CDMO Services:
Biologics; Cell & Gene Therapy Drug Substance Manufacturing (API); Drug Product Formulation (FDF); Analytical Development

Year Founded: 1848

Head Office: Madison, United States

Number of Facilities: 1

Facility locations: North America

Website: Visit the Waisman Biomanufacturing website

Linkedin: Connect on Linkedin

Current Capacity: Waisman supports Phase 1 and 2 manufacturing and has capacity for new business.